FDA Reattempts Guidance On Third-Party 510(k) Review Program
FDA is again attempting to outline its thinking on the 510(k) third-party review program in a new draft guidance. The program, which allows accredited organizations to conduct 510(k) reviews for certain products, has had a lackluster performance since it was first mandated by Congress in 1997.
You may also be interested in...
Lawmakers emphasized the need for a swift reauthorization of a combined US FDA device and drug user-fee reauthorization bill before the end of July, and released a clean discussion draft April 14 that mirrors the agreements reached by industry and the agency last summer.
US FDA's device center is facing new mandates and commitments to develop guidelines for industry. The guidance-development stipulations in the 21st Century Cures Act and the recent MDUFA IV user-fee agreement are detailed below.
Stay up-to-date on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. In the latest update, documents posted in September and October 2016.